氣喘與慢性阻塞性肺疾（COPD）治療藥物之全球市場 是由出版商BCC Research在2009年10月所出版的。
這份英文市場調查報告書包含176 pages 價格從美金4850起跳。
本研究報告詳細分析氣喘與慢性阻塞性肺疾（COPD）治療藥物之全球市場，並將2014為止之市場預測、已認可已上市之藥物等級、業界構造與企業檔案、法規環境等議題，分析整理如下。
第1章 導論
第2章 摘要
第3章 概論
- 介紹
- 慢性阻塞性肺疾
- 氣喘與COPD治療藥物之分類
- 藥物輸送方法
- 藥劑開發程序
- 疾病緩和藥劑
- 複雜的藥物管制程序
- 開發吸入性藥劑之技術層面
- 法規問題
- FDA藥劑安全性警告
- 業界導入企業
- 主要製造商
- 特殊藥劑製造商
- 小型企業
- 競爭因素
- 主要動向 等
第4章 疾病概要
- 氣喘之介紹
- 氣喘之分類
- 原因與風險因素
- 診斷
- 氣喘與COPD治療之認可藥劑等級 等
第5章 業界結構與競爭分析
- 業界結構
- 競爭動向
- 市場集中度與價格敏感度
- 進入市場之障礙
- 合作與併購
- 法規管理 等
第6章 以藥劑等級分類之市場
第7章 以患者分類之市場
第8章 以地域分類之市場
第9章 製藥管道概況
- 製藥管道開發
- 生物製藥
- 藥管局批准中之藥劑
- 第3相臨床試驗藥劑
- 第2相臨床試驗藥劑 等
第10章 企業檔案
Abstract
THIS REPORT:
- Provides an in-depth analysis of the global market for medications that
treat asthma and chronic obstructive pulmonary disease
- Contains global market forecasts through 2014 for medications that treat
asthma and chronic obstructive pulmonary disease
- Discusses the major classes of drugs currently approved and available in
the market including bronchodilators, anti-inflammatories and combination
therapies
- Includes information on industry structure along with company profiles
- Describes the regulatory environment for production and competition
factors that affect the industry.
SCOPE OF REPORT
The report intends to provide a current market snapshot and future
developments in the asthma and COPD drugs market over the period from 2007
through 2014. The report describes existing drug classes approved for these
indications, such as bronchodilators, anti-inflammatory drugs, and combination
drugs of inhaled corticosteroids and bronchodilators. The pipeline of drugs in
clinical trials for these indications is also presented and analyzed. The
report includes the following major sections: Disease overview Industry
structure and competitive analysis, including tiers of competition,
regulatory aspects, competitive factors, market unmet needs, challenges, and
trends Overall market revenue forecast and current market shares as well as
revenue forecast by major drug classes, disease indication, and geographical
regions In-depth analyses of current drug classes as well as a profiles of
major drugs Reviews and analyses of compounds in clinical trials, with an
emphasis on drugs in advanced stages of development.
METHODOLOGY
The analyses and data presented in this report are based on information
collected from a variety of industry sources, including pharmaceutical
manufacturers and end users. Secondary information sources include company
financials and documentation, SEC filings, trade organizations and
publications, online databases, and medical and scientific literature.
The base year for analysis and forecast is 2008. Revenue forecasts are
provided for the period 2009 to 2014. The forecasts are based on a
comprehensive analysis of a variety of market and product-specific factors,
including historical, current, and future trends; existing and undiagnosed
patient population; unmet market needs; existing products patent expiration
dates; the threat of generic substitution; new market entrants; and their
value proposition and differentiation.
ANALYST CREDENTIALS
Adriana Rusu holds a Master of Business Administration and a Master of Arts in
Chemistry degrees from the University of Arizona. She has more than 6 years of
experience in market analysis and management consulting for the life-sciences
industry. In her previous positions, Adriana consulted for various
life-sciences industry players, including major pharmaceutical companies such
as Pfizer, Johnson & Johnson, Novartis, and Merck. She has been quoted in
various publications, including Pharma Drug Discovery, Chemistry and Industry,
and Drug Discovery News. Adriana has also worked for several years in
scientific research and development and quality control for the chemicals
industry.
Table of Contents
Global Markets for Asthma and COPD Drugs
Chapter- 1: INTRODUCTION -- Complimentary
- STUDY GOALS AND OBJECTIVES
- REASONS FOR DOING THE STUDY
- SCOPE OF REPORT
- METHODOLOGY
- INTENDED AUDIENCE
- INFORMATION SOURCES
- ANALYST CREDENTIALS
- RELATED BCC REPORTS
- BCC ONLINE SERVICES
- DISCLAIMER
Chapter-2: SUMMARY
- Chapter TWO: SUMMARY
- SUMMARY TABLE GLOBAL MARKET FOR ASTHMA AND COPD DRUGS, THROUGH 2014 ($
MILLIONS)
- SUMMARY FIGURE GLOBAL MARKET FOR ASTHMA AND COPD DRUGS, 2007-2014 ($
MILLIONS)
Chapter-3: OVERVIEW
- INTRODUCTION
- ASTHMA
- CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- MEDICATION TREATMENT
- CLASSIFICATION OF ASTHMA AND COPD DRUGS
- Bronchodilators
- Anti-inflammatory Drugs
- Combination Inhaled Corticosteroids and Long-acting Beta-2 Agonists
(ICS/LABA)
- TABLE 1 MARKETED ASTHMA AND COPD DRUG CLASSES
- DRUG DELIVERY METHODS
- Metered-dose Inhaler
- Dry Powder Inhalers
- Nebulizers
- Oral and Injectable Drugs
- DRUG DEVELOPMENT PROCESS
- DISEASE-MODIFYING DRUGS - AN ELUSIVE QUEST
- COMPLEX REGULATORY DRUG APPROVAL PROCESS
- TECHNICAL ASPECTS IN THE DEVELOPMENT OF INHALED DRUGS
- REGULATORY ISSUES
- REMOVAL OF CFC-PROPELLED INHALERS
- FDA DRUG SAFETY WARNINGS
- INDUSTRY PLAYERS
- MAJOR DRUG MANUFACTURERS
- SPECIALTY PHARMACEUTICAL COMPANIES
- SMALLER COMPANIES
- COMPETITIVE FACTORS
- SIGNIFICANT TRENDS
- GLOBAL AGING POPULATION TO LEAD TO INCREASING ASTHMA AND COPD PREVALENCE
- NEW DRUG LAUNCHES TO OFFER ENHANCED TREATMENT OPTIONS
- PATENT EXPIRATIONS OF MAJOR DRUGS AND GENERIC DRUG LAUNCHES TO SLOW MARKET
GROWTH
Chapter-4: DISEASE OVERVIEW
- ASTHMA OVERVIEW
- CLASSIFICATION OF ASTHMA
- TABLE 2 CLASSIFICATION OF ASTHMA BY SYMPTOMS
- CAUSES AND RISK FACTORS
- DIAGNOSIS
- DRUG CLASSES APPROVED IN THE TREATMENT OF ASTHMA AND COPD
- TABLE 3 ASTHMA AND COPD DRUG CLASSES
- BRONCHODILATORS
- ANTI-INFLAMMATORY DRUGS
- COMBINATION THERAPIES OF BRONCHODILATORS AND ANTI-INFLAMMATORY DRUGS
- MEDICATION TREATMENT ALGORITHMS
- FIRST LINE OF THERAPY
- SECOND LINE OF THERAPY
- CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- CLASSIFICATION OF COPD
- TABLE 4 ASTHMA AND COPD DRUG CLASSES
- CAUSES AND RISK FACTORS
- DIAGNOSIS
- MEDICATION TREATMENT ALGORITHMS
- MEDICATION TREATMENT ALGORITHMS (CONTINUED)
Chapter-5: INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS
- INDUSTRY STRUCTURE
- TIERS OF COMPETITION
- TABLE 5 INDUSTRY STRUCTURE - MAJOR COMPETITORS AND MARKETED PRODUCTS
- TABLE 5 (CONTINUED)
- MARKET CONCENTRATION AND PRICE SENSITIVITY
- BARRIERS TO ENTRY
- Market Saturation and Competitiveness
- Sales and Marketing Capabilities
- Drug Formulation and Delivery
- Complex Regulatory and Drug Approval Process
- NOTABLE MERGERS AND ACQUISITIONS
- REGULATORY ASPECTS
- REMOVAL OF CFC-PROPELLED DRUGS AS REQUIRED BY THE MONTREAL PROTOCOL
ELIMINATED GENERIC COMPETITION FROM THE U.S. MARKET
- PATIENT SAFETY ISSUES LED TO MORE STRINGENT LABELING REVISIONS AND GUIDES
FOR ASTHMA AND COPD DRUGS
- COMPETITIVE FACTORS
- DELIVERY MODE AND CONVENIENCE
- PRODUCT EFFICACY AND DOSAGE FREQUENCY
- SAFETY PROFILE
- COMBINATION DRUGS
- PRICE
- MARKETING AND SALES EFFECTIVENESS
- MARKET CHALLENGES
- TECHNICAL- AND MARKET-SPECIFIC EXPERTISE REQUIRED TO COMPETE IN THIS
THERAPEUTIC AREA
- THE COMPLEX DRUG DEVELOPMENT PROCESS
- MARKET UNMET NEEDS
- DISEASE-MODIFYING DRUGS
- SUPERIOR EFFICACY DRUGS
- IMPROVED SAFETY PROFILE DRUGS
- IMPROVED DRUG DELIVERY MODALITIES
- IMPROVED QUALITY OF LIFE FOR PATIENTS
- MARKET TRENDS
- TABLE 6 MARKET TRENDS IN THE ASTHMA/COPD MEDICATION MARKET
- INCREASED PREVALENCE OF ASTHMA AND COPD IS EXPECTED TO DRIVE MARKET GROWTH
GLOBALLY
- ENHANCED PATIENT AWARENESS IS EXPECTED TO LEAD TO GREATER DIAGNOSIS AND
TREATMENT RATES
- NEW PRODUCT LAUNCHES WITH ENHANCED CONVENIENCE AND SAFETY PROFILES ARE
EXPECTED TO EXPAND THE OVERALL MARKET
- REMOVAL OF CFC-PROPELLED INHALERS FROM THE MARKET IS EXPECTED TO DRIVE
MARKET GROWTH
- CHANGES IN REIMBURSEMENT RATES AFFECT DRUG REVENUES
- LOSS OF PATENT PROTECTION FOR MAJOR BLOCKBUSTER DRUGS IS EXPECTED TO SLOW
THE OVERALL MARKET GROWTH
- TOTAL MARKET REVENUES AND FORECAST
- TOTAL MARKET REVENUES
- TABLE 7 GLOBAL MARKET FOR ASTHMA AND COPD DRUGS, BY SEGMENT, 2008 ($ MILLIONS)
- FIGURE 1 GLOBAL MARKET FOR ASTHMA AND COPD DRUGS, BY SEGMENT, 2008 ($ MILLIONS)
- MARKET SHARES
- TABLE 8 GLOBAL MARKET SHARES OF LEADING COMPANIES IN ASTHMA AND COPD MEDICATION, 2008
- FIGURE 2 GLOBAL MARKET SHARES OF LEADING COMPANIES IN ASTHMA AND COPD MEDICATION, 2008 (%)
- MARKET FORECAST
- TABLE 9 GLOBAL MARKET FOR ASTHMA AND COPD DRUGS, THROUGH 2014 ($ MILLIONS)
- FIGURE 3 GLOBAL MARKET FOR ASTHMA AND COPD DRUGS, 2007-2014 ($ MILLIONS)
- Forecast Assumptions
- Existing Drugs Revenue Increases
- Patent Expirations of Major Drugs
- Expected New Drug Launches
- Expected New ... (Continued)
- Expected New ... (Continued)
Chapter-6: MARKETS BY DRUG CLASSES
- BRONCHODILATORS
- OVERVIEW
- MARKET REVENUES AND FORECAST
- TABLE 10 MARKET SHARES OF LEADING COMPANIES SUPPLYING BRONCHODILATORS, 2008
- FIGURE 4 MARKET SHARES OF LEADING COMPANIES SUPPLYING BRONCHODILATORS, 2008 (%)
- TABLE 11 GLOBAL MARKET FOR BRONCHODILATORS, THROUGH 2014 ($ MILLIONS)
- FIGURE 5 GLOBAL MARKET FOR BRONCHODILATORS, 2007-2014 ($ MILLIONS)
- SHORT-ACTING BETA-2 AGONISTS
- Overview
- TABLE 12 SHORT-ACTING BETA-2 AGONISTS INDUSTRY STRUCTURE, 2009
- Market Revenues and Forecast
- TABLE 13 MARKET SHARES OF LEADING COMPANIES SUPPLYING SHORT-ACTING BETA-2 AGONISTS, 2008 (%)
- FIGURE 6 MARKET SHARES OF LEADING COMPANIES SUPPLYING SHORT-ACTING BETA-2 AGONISTS, 2008 (%)
- TABLE 14 GLOBAL MARKET FOR SHORT-ACTING BETA-2 AGONISTS, THROUGH 2014 ($ MILLIONS)
- FIGURE 7 GLOBAL MARKET FOR SHORT-ACTING BETA-2 AGONISTS, 2007-2014 ($ MILLIONS)
- Products Analysis
- ProAir HFA
- TABLE 15 PROAIR HFA ANALYSIS
- Xopenex
- TABLE 16 XOPENEX ANALYSIS
- LONG-ACTING BETA-2 AGONISTS
- Overview
- TABLE 17 LONG-ACTING BETA-2 AGONISTS INDUSTRY STRUCTURE, 2009
- Market Revenues and Forecast
- Market Revenues and Forecast (Continued)
- TABLE 18 MARKET SHARES OF LEADING COMPANIES SUPPLYING LONG-ACTING BETA-2 AGONISTS, 2008
- FIGURE 8 MARKET SHARES OF LEADING COMPANIES SUPPLYING LONG-ACTING BETA-2 AGONISTS, 2008 (%)
- TABLE 19 GLOBAL MARKET FOR LONG-ACTING BETA-2 AGONISTS, THROUGH 2014 ($ MILLIONS)
- FIGURE 9 GLOBAL MARKET FOR LONG-ACTING BETA-2 AGONISTS, 2007-2014 ($ MILLIONS)
- Products Analysis
- Foradil
- Foradil (Continued)
- TABLE 20 FORADIL AEROLIZER ANALYSIS
- Brovana
- TABLE 21 BROVANA ANALYSIS
- ANTICHOLINERGICS AND COMBINATION ANTICHOLINERGICS/SHORT-ACTING BETA-2
AGONISTS
- Overview
- TABLE 22 ANTICHOLINERGICS AND COMBINATION ANTICHOLINERGICS/SABA INDUSTRY STRUCTURE, 2009
- Market Revenues and Forecast
- TABLE 23 MARKET SHARES OF LEADING COMPANIES SUPPLYING ANTICHOLINERGICS, 2008
- FIGURE 10 MARKET SHARES OF LEADING COMPANIES SUPPLYING ANTICHOLINERGICS, 2008 (%)
- TABLE 24 GLOBAL MARKET FOR ANTICHOLINERGICS, THROUGH 2014 ($ MILLIONS)
- FIGURE 11 GLOBAL MARKET FOR ANTICHOLINERGICS, 2007-2014 ($ MILLIONS)
- Products Analysis
- Spiriva
- TABLE 25 SPIRIVA ANALYSIS
- ANTI-INFLAMMATORY DRUGS
- OVERVIEW
- MARKET REVENUES AND FORECAST
- TABLE 26 MARKET SHARES OF LEADING COMPANIES SUPPLYING ANTI-INFLAMMATORY DRUGS, 2008
- FIGURE 12 MARKET SHARES OF LEADING COMPANIES SUPPLYING ANTI-INFLAMMATORY DRUGS, 2008 (%)
- TABLE 27 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS, THROUGH 2014 ($ MILLIONS)
- FIGURE 13 GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS, THROUGH 2014 ($ MILLIONS)
- INHALED CORTICOSTEROIDS
- Overview
- TABLE 28 INHALED CORTICOSTEROIDS INDUSTRY STRUCTURE, 2009
- Market Revenues and Forecast
- TABLE 29 MARKET SHARES OF LEADING COMPANIES SUPPLYING INHALED CORTICOSTEROIDS, 2008 (%)
- FIGURE 14 MARKET SHARES OF LEADING COMPANIES SUPPLYING INHALED CORTICOSTEROIDS, 2008 (%)
- TABLE 30 GLOBAL MARKET FOR INHALED CORTICOSTEROIDS, THROUGH 2014 ($ MILLIONS)
- FIGURE 15 GLOBAL MARKET FOR INHALED CORTICOSTEROIDS, 2007-2014 ($ MILLIONS)
- Products Analysis
- Pulmicort
- TABLE 31 PULMICORT ANALYSIS
- Flovent/Flixotide
- TABLE 32 FLOVENT ANALYSIS
- LEUKOTRIENE MODIFIERS
- Overview
- TABLE 33 LONG-ACTING BETA-2 AGONISTS INDUSTRY STRUCTURE, 2009
- Market Revenues and Forecast
- TABLE 34 MARKET SHARES OF LEADING COMPANIES SUPPLYING LEUKOTRIENE MODIFIERS, 2008 (%)
- FIGURE 16 MARKET SHARES OF LEADING COMPANIES SUPPLYING LEUKOTRIENE MODIFIERS, 2008 (%)
- TABLE 35 GLOBAL MARKET FOR LEUKOTRIENE MODIFIERS, THROUGH 2014 ($ MILLIONS)
- FIGURE 17 GLOBAL MARKET FOR LEUKOTRIENE MODIFIERS, THROUGH 2014 ($ MILLIONS)
- Product Analysis
- Singulair
- TABLE 36 SINGULAIR ANALYSIS
- BIOLOGICAL DRUGS
- Overview
- Market Revenues and Forecast
- TABLE 37 GLOBAL MARKET FOR BIOLOGICAL DRUGS, THROUGH 2014 ($ MILLIONS)
- FIGURE 18 GLOBAL MARKET FOR BIOLOGICAL DRUGS, 2007-2014 ($ MILLIONS)
- Product Analysis
- Xolair
- COMBINATION ICS/LABA DRUGS
- OVERVIEW
- TABLE 39 COMBINATION ICS/LABA INDUSTRY STRUCTURE, 2009
- Market Revenues and Forecast
- TABLE 40 MARKET SHARES OF LEADING COMPANIES SUPPLYING COMBINATION ICS/LABA, 2008
- FIGURE 19 MARKET SHARES OF LEADING COMPANIES SUPPLYING COMBINATION ICS/LABA, 2008 (%)
- Market Revenues and Forecast (Continued)
- TABLE 41 GLOBAL MARKET FOR COMBINATION ICS/LABA DRUGS, THROUGH 2014 ($ MILLIONS)
- FIGURE 20 GLOBAL MARKET FOR COMBINATION ICS/LABA DRUGS, 2007-2014 ($ MILLIONS)
- Products Analysis
- Advair/Seretide
- TABLE 42 ADVAIR/SERETIDE ANALYSIS
- Symbicort
- Symbicort (Continued)
- TABLE 43 SYMBICORT ANALYSIS
Chapter-7: MARKETS BY DISEASE
- ASTHMA DRUGS MARKET
- ASTHMA DRUGS
- MARKET REVENUES
- TABLE 44 GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY DISEASE, 2008 ($ MILLIONS/%)
- FIGURE 21 GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY DISEASE, 2008 (%)
- MARKET SHARES
- TABLE 45 MARKET SHARES OF LEADING COMPANIES SUPPLYING THE ASTHMA DRUGS MARKET, 2008
- FIGURE 22 MARKET SHARES OF LEADING COMPANIES SUPPLYING THE ASTHMA DRUGS MARKET, 2008 (%)
- REVENUE FORECAST
- New Branded Drugs Launches
- Generic Drug Launches
- TABLE 46 GLOBAL MARKET ASTHMA PRESCRIPTION DRUGS, THROUGH 2014 ($ MILLIONS)
- FIGURE 23 GLOBAL MARKET ASTHMA PRESCRIPTION DRUGS, 2007-2014 ($ MILLIONS)
- CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) DRUGS MARKET
- COPD DRUGS
- MARKET OVERVIEW
- TABLE 47 GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY DISEASE, 2008 ($ MILLIONS)
- MARKET SHARES
- TABLE 48 MARKET SHARES OF LEADING COMPANIES SUPPLYING COPD DRUGS, 2008 (%)
- FIGURE 24 MARKET SHARES OF LEADING COMPANIES SUPPLYING COPD DRUGS, 2008 (%)
- REVENUE FORECAST
- New Branded Drug Launches
- New Branded Drug Launches (Continued)
- Generic Drug Launches
- TABLE 49 GLOBAL MARKET FOR COPD PRESCRIPTION DRUGS, THROUGH 2014 ($ MILLIONS)
- FIGURE 25 GLOBAL MARKET FOR COPD PRESCRIPTION DRUGS, 2007-2014 ($ MILLIONS)
Chapter-8: MARKETS BY GEOGRAPHICAL REGIONS
- USA
- MARKET OVERVIEW: PRODUCTS, SIGNIFICANT ASPECTS
- Market Overview
- TABLE 50 MARKET SHARES OF LEADING COMPANIES IN THE U.S. SUPPLYING ASTHMA AND COPD PRESCRIPTION DRUGS, 2008 (%)
- FIGURE 26 MARKET SHARES OF LEADING COMPANIES IN THE U.S. SUPPLYING ASTHMA AND COPD PRESCRIPTION DRUGS, 2008 (%)
- Products
- Significant Aspects
- REVENUE FORECAST
- Revenue forecast (Continued)
- TABLE 51 UNITED STATES MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS, THROUGH 2014 ($ MILLIONS)
- FIGURE 27 UNITED STATES MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS, 2007-2014 ($ MILLIONS)
- EUROPEAN UNION
- MARKET OVERVIEW: PRODUCTS, SIGNIFICANT ASPECTS
- Market Overview
- TABLE 52 MARKET SHARES OF LEADING COMPANIES IN THE EUROPEAN UNION SUPPLYING ASTHMA AND COPD PRESCRIPTION DRUGS, 2008 (%)
- FIGURE 28 MARKET SHARES OF LEADING COMPANIES IN THE EUROPEAN UNION SUPPLYING ASTHMA AND COPD PRESCRIPTION DRUGS, 2008 (%)
- Products
- Significant Aspects
- REVENUE FORECAST
- TABLE 53 EU MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS, THROUGH 2014. ($ MILLIONS)
- FIGURE 29 EU MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS, 2007-2014 ($ MILLIONS)
- REST OF THE WORLD MARKET
- MARKET OVERVIEW: PRODUCTS, SIGNIFICANT ASPECTS
- Market Overview
- TABLE 54 MARKET SHARES OF LEADING COMPANIES SUPPLYING ASTHMA AND COPD PRESCRIPTION DRUGS TO ROW, 2008 (%)
- FIGURE 30 MARKET SHARES OF LEADING COMPANIES SUPPLYING ASTHMA AND COPD PRESCRIPTION DRUGS TO ROW, 2008 (%)
- Products
- Significant Aspects
- REVENUE FORECAST
- TABLE 55 REST OF WORLD MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS, THROUGH 2014 ($ MILLIONS)
- FIGURE 31 REST OF WORLD MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS, 2007-2014 ($ MILLIONS)
Chapter-9: PIPELINE REVIEW
- PIPELINE OVERVIEW
- BIOLOGICAL DRUGS
- PDE-4 (PHOSPHODIESTERASE-4) INHIBITORS
- CHEMOKINE RECEPTOR ANTAGONISTS
- CRTH2 RECEPTOR ANTAGONISTS
- KINASE INHIBITORS
- BRONCHODILATORS
- DRUGS FILED FOR REGULATORY APPROVAL
- DRUGS IN PHASE III CLINICAL TRIALS
- DRUGS IN PHASE II CLINICAL TRIALS
- TABLE 56 LONG-ACTING BRONCHODILATORS PIPELINE, 2009
- TABLE 56 (CONTINUED)
- COMBINATION DRUGS OF INHALED CORTICOSTEROIDS AND LONG-ACTING
BRONCHODILATORS
- DRUGS FILED FOR REGULATORY APPROVAL
- DRUGS IN PHASE III CLINICAL TRIALS
- DRUGS IN PHASE II CLINICAL TRIALS
- TABLE 57 COMBINATION ICS/LABA DRUGS PIPELINE, 2009
- TABLE 57 (CONTINUED)
- OTHER DRUG CLASSES
- DRUGS FILED FOR REGULATORY APPROVAL
- DRUGS IN PHASE II CLINICAL TRIALS
- 5-Lipoxygenase (5-LO) Inhibitors
- Phosphodiesterase-4 (PDE-4) Inhibitors
- CRTH2 Receptor Antagonists
- Biological Drugs
- Monoclonal Antibodies
- Immunotherapy/Vaccines
- RNA-silencing
- Stem Cells Therapy
- Other Mechanisms
- TABLE 58 BIOLOGICAL DRUGS PIPELINE, 2009
- TABLE 58 (CONTINUED)
- TABLE 59 OTHER DRUG CLASSES PIPELINE, PHASE II, 2009
- TABLE 59 (CONTINUED)
- DRUGS IN PHASE I CLINICAL TRIALS
- Drugs in Phase I Clinical Trials (Continued)
- TABLE 60 OTHER DRUG CLASSES PIPELINE, PHASE I, 2009
Chapter-10: COMPANY PROFILES
- ABBOTT LABORATORIES
- AEROVANCE, INC.
- ALKERMES, INC.
- ALMIRALL, S.A.
- ALTAIR THERAPEUTICS, INC.
- AMGEN INC.
- ARGENTA DISCOVERY, LTD.
- ASTRAZENECA
- ASTRAZENECA PHARMACEUTICALS, LP
- BOEHRINGER INGELHEIM GMBH
- BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
- CYTOS BIOTECHNOLOGY AG
- FOREST LABORATORIES, INC.
- GENENTECH, INC.
- GLAXO WELLCOME U.K., LTD.
- GLAXOSMITHKLINE U.S.
- ICAGEN, INC.
- MEDICINOVA
- MEDIMMUNE
- MERCK & CO., INC.
- NOVARTIS PHARMA
- NOVARTIS CORPORATION
- NOVARTIS PHARMACEUTICALS CORPORATION
- NYCOMED INTERNATIONAL MANAGEMENT GMBH
- OSIRIS THERAPEUTICS, INC.
- PFIZER, INC.
- SCHERING-PLOUGH CORPORATION
- SEPRACOR, INC.
- SKYEPHARMA PLC
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- TEVA PHARMACEUTICALS USA
- THERAVANCE
- TOPIGEN PHARMACEUTICALS, INC.
- VECTURA GROUP PLC
- VECTURA GROUP PLC (CONTINUED)
|
